Aurinia Pharmaceuticals Inc (AUPH) Stock Rating Upgraded by Vetr Inc.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was upgraded by equities researchers at Vetr from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The firm currently has a $6.64 price target on the biotechnology company’s stock. Vetr‘s price target suggests a potential upside of 5.90% from the company’s previous close.
A number of other brokerages have also issued reports on AUPH. HC Wainwright cut their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 18th. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Cantor Fitzgerald set a $14.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $9.71.
Shares of Aurinia Pharmaceuticals (AUPH) traded down 0.79% during midday trading on Wednesday, hitting $6.27. The stock had a trading volume of 569,779 shares. The firm’s market cap is $523.45 million. Aurinia Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $10.54. The firm’s 50 day moving average price is $6.22 and its 200 day moving average price is $6.66.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The firm had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. On average, equities research analysts expect that Aurinia Pharmaceuticals will post ($0.94) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. NEA Management Company LLC raised its position in Aurinia Pharmaceuticals by 18.2% in the first quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company’s stock valued at $35,294,000 after purchasing an additional 740,740 shares during the period. AWM Investment Company Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $2,202,000. Quantbot Technologies LP purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $275,000. Two Sigma Securities LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the first quarter worth $240,000. Finally, Morgan Stanley increased its position in shares of Aurinia Pharmaceuticals by 11,061.7% during the first quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock worth $3,273,000 after acquiring an additional 442,138 shares during the period. 27.83% of the stock is currently owned by institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.